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Physician-modiﬁed endovascular devices are becoming commonplace in a modern climate where innovation outpaces
regulated technological advancement. Off-label use of medical devices occurs on a daily basis throughout many institu-
tions across the United States and when performed by physicians, is both legal and unregulated. The purpose of this
invited commentary is to review the regulatory, compliance, and legal issues regarding the practice of medical device
modiﬁcation. (J Vasc Surg 2013;57:829-31.)Immediate stent graft modiﬁcation with fenestrations
was initially described in 2006 by Krasi Ivancev and
colleagues in a series of three patients.1 In April of 2007,
we began treating patients with asymptomatic, symptom-
atic, or ruptured juxtarenal aortic aneurysms by modifying
a Food and Drug Administration (FDA)-approved medical
device (Zenith Flex; Cook, Inc, Bloomington, Ind) with
the creation of fenestrations to maintain branch vessel
patency (Fig). These procedures were performed on
patients who were deemed not to be suitable candidates
for open surgical repair and had no other treatment
options.2 The purpose of this invited commentary is to
review the regulatory, compliance, and legal issues
regarding the practice of medical device modiﬁcation.
Off-label use of medical devices occurs on a daily basis
throughout many institutions across the United States
and when performed by physicians, is both legal and unreg-
ulated. This is according to the “practice of medicine
doctrine,” which was explicitly articulated in the Food
and Drug Administration Modernization Act of 1997.3
“Nothing in this chapter shall be construed to limit or
interfere with the authority of a health care practitioner to
prescribe or administer any legally marketed device to
a patient for any condition or disease within a legitimate
health care practitioner-patient relationship.”3
What actually composes a “legitimate health care
practitioner-patient relationship” is poorly deﬁned in thethe Division of Vascular Surgery, Department of Surgery, University
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is legal and unregulated does not necessarily mean that it is
safe, smart, well-justiﬁed, or legal with respect to billing
practices. The defense of an “unsafe” off-label use would
actually be an ex post facto liability matter, not a regulatory
matter. The author will address the separate but equally
important topic of product liability later in this article.
According to the FDA, device modiﬁcations are a regulated
activity,3 although within the FDA’s regulatory discretion,
it has not actively pursued in-house device modiﬁcations. A
critically important feature of regulatory discretion is that it
can change without notice, and/or be exercised sporadi-
cally. If everything goes well, the FDA will not become
interested, but if something bad happens, the FDA will
become interested and have the unlimited authority to
act. They could very well ﬁnd the practitioner out of
compliance even though they had no previous interest in
the provider’s activities. The Food and Drug Administra-
tion Modernization Act of 1997 further states that its
provisions do nothing to limit the existing FDA regulatory
powers.3
In general, the FDA has the authority over a device and
any person or facility where anyone is engaged in the manu-
facture, preparation, propagation, compounding, assembly,
or processing of a device intended for human use (21 CFR
807.20). Title 21 CFR 807.81 makes it crystal clear that
anyone introducing a medical device into commercial distri-
bution must meet the existing pre-market requirements.
However, physicians who produce or alter a device for
use within their own practice are exempted from the pre-
market notiﬁcation requirement (21 CFR 807.65(d)), but
they are not exempted from the premarket approval
requirements for a class III medical device.
Even though physicians may modify a device and have
a good outcome, the Center for Medicaid and Medicare
Services (CMS), a sister governmental organization to
the FDA without any reciprocal inﬂuence, may choose
not to reimburse the practitioner or the institution for
the procedure, citing that the device modiﬁcations are
“investigational.” Furthermore, it is considered fraudulent
to bill the CMS for services that are investigational without829
Fig. Physician modiﬁcation of a currently available Food and
Drug Administration-approved stent graft. A, Creation of a fenes-
tration for the superior mesenteric artery with an ophthalmic
bovie. B, Suturing of a radio-opaque marker around the same
fenestration to aid in ﬁxation and visibility. This device was
modiﬁed under an investigator-sponsored investigational device
exemption.
JOURNAL OF VASCULAR SURGERY
830 Starnes March 2013formal prior approval from CMS. This is exactly what
happened at the University of Washington in 2009 (CMS
chose not to reimburse our institution for the procedures),
after carrying out dozens of physician-modiﬁed endovascu-
lar graft (PMEG) procedures beginning in April 2007. The
only recourse to continue to treat patients with PMEG was
to pursue a formal investigational device exemption (IDE)
with oversight from the FDA.
The issue of product liability is germane to this topic.
Many people have had medical devices used to better their
health only to suffer injuries related to the use of that same
device. Sometimes, these injuries serve as the basis for
a product liability claim on behalf of the treated patient.
All defective product liability claims come in three varieties.
Product liability claims resulting from defective medical
devices are based on one or more of the following three
entities:
1. Defectively manufactured medical devices. These are
devices that were manufactured improperly or
somehow damaged during the manufacturing
process. This may have happened because of an error
in the manufacturing process, a problem withshipping of the device, or an error that occurs in
the hospital setting during device implantation or
use (failure of quality control).
2. Medical devices with a defective design. These are
devices that were properly manufactured but have
an inherently and unreasonably dangerous design
that results in injury. Sometimes, the device will
have been on the market for a long period of time
but then fails in some way and causes serious injury.
3. Defectively marketed medical devices. “Marketing” of
a medical device refers to any recommendation,
warning, lack of warning, or instruction concerning
the use of that device by a potential defendant. This
claim category involves anything from a failure to
provide adequate or accurate warnings regarding the
danger posed by the medical device to a failure to
provide adequate instructions regarding its safe and
appropriate use.4
Every person or entity involved in the “chain of distri-
bution” of a medical device (the path the medical device
took from the manufacturer to the consumer), is poten-
tially liable for the claim. This includes the manufacturer,
the medical sales representative who counsels and makes
recommendations to the treating physician, the doctor,
and the hospital.5 The use of a new FDA-approved device
in the hands of an inexperienced operator can also lead to
potential liability. With PMEG, since the device had been
modiﬁed after the manufacturing process and used outside
the instructions for use, the manufacturer essentially
became exempt from any product liability claim. It is there-
fore extremely prudent on the part of the physician, in this
case practicing PMEG, to initiate an IDE for the proper
study of the safety and effectiveness of the technique.
An investigator-initiated IDE requires extensive regula-
tory and compliance knowledge on the part of the principal
investigator. As an IDE holder, the physician is not simply
a site investigator but also the sponsor of the clinical study.
Sponsor responsibilities are considerably different than site-
investigator responsibilities. When our team ﬁnally decided
to move forward with the application process for an IDE,
we had no concept of the amount of work that would
eventually be required to win approval and sustain the
entire process. The cost of running an IDE is considerable
and includes a research coordinator’s salary and monitoring
service fees. Stafﬁng requirements, secure database
management, clinical events committees, data safety moni-
toring boards, reporting of adverse events and deviations
from the predescribed study plan, and annual progress
reports add up to a mountain of work for even the most
motivated of individuals. A list of steps for obtaining an
IDE at our institution is listed in the Table. Furthermore,
we quickly realized after receiving approval to conduct
the IDE that our team was subject to inspection by the
FDA at any time. Interestingly, the author used to believe
that the FDA was a prohibitive entity, but after working
closely with this organization for over 2 years, we now
believe the FDA to be incredibly facilitative. The FDA
Table. Steps for obtaining an IDE at the University of Washington
1. Review FDA website for the appropriate submission format to use http://www.fda.gov/MedicalDevices/default.htm.
2. Write protocol, obtain references, and justiﬁcation for why this study is being proposed.
3. Request trusted colleagues to review the protocol for accuracy and readability.
4. After protocol is written, write CRFs.
5. Submit protocol to IRB and at the same time, request an in-person meeting to present directly to them. With nonsponsored
studies, the IRB may have many questions and it is easier to answer them in person rather than have delay of approval by
a back-and-forth dialogue. This may not be possible with all IRBs, but it does help pave the way to approval.
6. Obtain “conditional approval” from the IRB meaning that the study cannot begin until FDA approval is obtained and the FDA-
amended protocol is resubmitted to the IRB.
7. Submit an IRB conditional approval letter and pre-IDE application to the FDA. Follow the guidelines on the FDA.gov website.
8. Once comments and suggestions are received back from the FDA, submit full IDE application to the FDA. One must follow new
IDE submission requirements or one will have a delay in getting approval.
9. The budget can be done at any time. If one needs buy-in from the host institution, start this process after the protocol and case
report forms are written (the coordinator/budget personnel will have a better idea of the time involved if they have these two sets
of documents). In truth, one really needs the institutional buy-in before even starting the protocol-writing process.
10. Once FDA approval is received, submit this approval letter to the IRB for their ﬁnal approval. One may get approval to start the
study, but there may be requested changes or corrections to make to the protocol.
11. Once ﬁnal IRB approval is received, submit this document back to the FDA. The initial FDA approval letter will state that the
investigator can begin the study after the FDA has received the ﬁnal approval from the host institution IRB, and they (the FDA)
have acknowledged receipt of this approval.
12. Submit to CMS part A and B. Currently, part A can be submitted electronically, but part B needs to be sent in paper form. Part B
will not be approved until part A approval is received. (We recommend simultaneously submitting part A electronically and part B
in paper form. Once part A approval is received, the part A approval letter can be sent to part B personnel.)
CRF, Case report form; FDA, Food and Drug Administration; IDE, investigational device exemption; IRB, institutional review board.
Investigators should check the FDA website, their individual IRB requirements, and their regional Medicare submission requirements.
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physicians successfully treat their patients. Our institution
has recently received FDA approval of a second IDE to
perform device modiﬁcation in patients presenting with
thoracoabdominal aneurysms.
In conclusion, the practice of device modiﬁcation is
legal and unregulated in most instances. However, the
FDA has wide and unlimited authority to intervene when
patient safety or effectiveness of the device becomes
a concern. The CMS, depending on the regional carrier,
may choose to fully compensate or pay absolutely nothing
for these cases based on an assessment of “investigational
use.” Any practitioner who chooses to modify an existing
FDA-approved medical device outside of an IDE should
weigh heavily the ramiﬁcations of a product liability claim
and/or a criminal or civil liability claim, as the manufac-
turer becomes exempt once the device has been modiﬁed.
It is the author’s opinion that physicians performing devicemodiﬁcation of the nature described herein are obliged to
obtain an IDE.
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